SUMMARY Erbium-169 was compared with triamcinolone hexacetonide in the topical treatment of 32 patients suffering from rheumatoid arthritis. Erbium-169 was injected into 83 and triamcinolone hexacetonide into 54 proximal interphalangeal or metacarpophalangeal joints. Both treatments produced alleviation ofjoint pain and swelling and improvement of grip strength. At every check-up (1-18 months) the percentage of remissions was higher after triamcinolone hexacetonide injection than after erbium-169. The difference was significant at 1, 3, and 6 months.
Intra-articular injection of the beta-emitter erbium-169 (e69Er) has been used with success in the treatment of rheumatoid finger joints (Menkes et al., 1974) . The result after 1 year was very good or good in 54% of cases. The radionuclide was injected with prednisolone acetate. In another study the effect of 169Er (+ prednisolone acetate) was compared with that of saline (+ steroid) . The rate of improvement after 6-12 months was significantly higher with 169Er than with saline (Menkes et al., 1977) .
In the present study we have evaluated the effects of 169Er in comparison with triamcinolone hexacetonide (TCHA). We also calculated the radiation doses in the synovium and axillary lymph nodes.
Patients and methods 169Er has a half-life of 9 5 days. It radiates betaparticles with a maximum energy of 340 keV (av. 100). The effective half-value attenuation layer is 0'1 mm. The agent is administered as a colloidal citrate suspension, pH 7, mean particle diameter 10 nm (Commissariat A l'energie atomique, Saclay).
For the proximal interphalangeal joints the dose used was 0 25 mCi and for the metacarpophalangeal joints 0 * 5 mCi. After treatment the joint was splinted for 3 days to reduce leakage of the radionuclide (Oka et al., 1971) . The leakage of the injected 169Er activity was measured in the axillary lymph nodes 3-5 days after treatment. No steroid was injected with 169Er. The series comprised 32 patients (10 males and 22 females) suffering from rheumatoid arthritis. They were all seropositive and fulfilled the criteria of the American Rheumatism Association for definite or classical rheumatoid arthritis. Their ages ranged from 36 to 74 years (average 53) and the duration of the disease from 1/2 to 23 years (average 8).
The total number of treated joints was 137. Of these, 83 (48 proximal interphalangeal + 35 metacarpophalangeal) were treated with 169Er, and 54 (33 proximal interphalangeal + 21 metacarpophalangeal) with TCHA. Effusion was palpable in all the treatedjoints. The pretreatment data, which7show that the groups were comparable, are given in the Table 1 . The x-ray grading was made according to Steinbrocker. finger joints led to changes in all the parameters studied. The changes were more pronounced with TCHA than with 169Er, especially at 1, 3, and 6 months. The effect of TCHA appeared quickly, with a climax around 3 months after the injection, followed by a gradual deterioration. After 169Er the improvement in treated joints appeared later than after TCHA. The number of excellent results (remissions) increased significantly from 1 to 12 months and that of failures decreased. At 12 and 18 months no signficant difference could be found between the 2 groups in the general evaluation (pain and effusion), ring size, or grip strength. At every check-up the percentage of excellent results was higher after TCHA treatment than after 169Er (Tables 2, 3 , 4, Figs. 1, 2, 3 .) The mean ESR did not change during the follow-up period of 12 months (41-40 mm/h).
The results did not seem to depend on the radiological grade of the treated joints. A deterioration of the x-ray grade was observed in 5 joints during the follow-up period of 12 months. Three of these joints had been treated with '69Er and 2 with TCHA.
No side effects were noticed after TCHA injection. A bullous eruption developed in 2 fingers of a patient 3 weeks after injection of '69Er; the symptoms subsided in about 2 weeks. In another patient a slight erythema was observed at the site of 169Er injection at check-up after 1 month. knees (Gumpel, 1973) . Both in knees (90Y) and in TIME I months finger joints e69Er) the radioactivity concentration 2 Changes in ring size (mm) has been about 0 2-0 4 mCi/ml of cavity volume.
However, the total radiation energy of 90Y in the synovial membrane is about 6 times as high as that p of 169Er (Oka et al., 1971) . For small joints 90Y is tENGTH contraindicated because of its high penetration, 5-* which increases the hazards of radiation in periarticular tissue.
In finger joints TCHA treatment seems to give more remissions and fewer failures than the same agent in the knee (Anttinen and Oka, 1975 with a long-acting steroid such as TCHA. TCHA is TIME / months simple to use, effective, and devoid of risks. Fig. 3 Changes in grip strength (mmHg).
RADIATION DOSES
For a cavity area of 1 cm2 (proximal interphalangeal joint) and with the injected activity of 0 25 mCi the synovial radiation dose is about 9000 rad at a depth of 0 5 mm. The corresponding value for a cavity area of 3 cm2 (metacarpophalangeal joint), with the 0 5 mCi activity, is 6000 rad. The doses in axillary lymph nodes are, respectively, about 35 and 70 rad/ % of escaped activity. The lymph node accumulation varied between 3 and 14 % leading to a radiation dose of 100-1000 rad. Discussion Menkes et al. (1977) have shown that 169Er injection is superior to saline in rheumatoid finger joints. In the present study both 169Er and the long-acting steroid TCHA produced marked improvements in
